Lamont Rachel, Rosic Tea, Sanger Nitika, Samaan Zainab
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Schizophr Bull Open. 2020 Jan;1(1):sgaa007. doi: 10.1093/schizbullopen/sgaa007. Epub 2020 Mar 2.
Substance use disorders are highly prevalent among individuals with psychotic disorders and are associated with negative outcomes. This study aims to explore differences in characteristics and treatment outcomes for individuals with psychotic disorders when compared with individuals with other nonpsychotic psychiatric disorders enrolled in treatment for opioid use disorder (OUD).
Data were collected from a prospective cohort study of 415 individuals enrolled in outpatient methadone maintenance treatment (MMT). Psychiatric comorbidity was assessed using the Mini-International Neuropsychiatric Interview. Participants were followed for 12 months. Participant characteristics associated with having a psychotic disorder versus another nonpsychotic psychiatric disorder were explored by logistic regression analysis.
Altogether, 37 individuals (9%) with a psychotic disorder were identified. Having a psychotic disorder was associated with less opioid-positive urine drug screens (odds ratio [OR] = 0.97, 95% confidence interval [CI] = 0.95, 0.99, = .046). Twelve-month retention in treatment was not associated with psychotic disorder group status (OR = 0.73, 95% CI = 0.3, 1.77, = .485). Participants with psychotic disorders were more likely to be prescribed antidepressants (OR = 2.12, 95% CI = 1.06, 4.22, = .033), antipsychotics (OR = 3.57, 95% CI = 1.74, 7.32, = .001), mood stabilizers (OR = 6.61, 95% CI = 1.51, 28.97, = .012), and benzodiazepines (OR = 2.22, 95% CI = 1.11, 4.43, = .024).
This study contributes to the sparse literature on outcomes of individuals with psychotic disorders and OUD-receiving MMT. Rates of retention in treatment and opioid use are encouraging and contrast to the widely held belief that these individuals do more poorly in treatment. Higher rates of coprescription of sedating and QTc-prolonging medications in this group may pose unique safety concerns.
物质使用障碍在患有精神障碍的个体中高度流行,且与不良后果相关。本研究旨在探讨与参加阿片类物质使用障碍(OUD)治疗的其他非精神性精神障碍个体相比,患有精神障碍的个体在特征和治疗结果上的差异。
数据来自一项对415名参加门诊美沙酮维持治疗(MMT)的个体进行的前瞻性队列研究。使用迷你国际神经精神病学访谈评估精神科合并症。对参与者进行了12个月的随访。通过逻辑回归分析探讨与患有精神障碍而非其他非精神性精神障碍相关的参与者特征。
共识别出37名(9%)患有精神障碍的个体。患有精神障碍与阿片类物质阳性尿液药物筛查结果较少相关(优势比[OR]=0.97,95%置信区间[CI]=0.95,0.99,P=.046)。治疗12个月的留存率与精神障碍组状态无关(OR=0.73,95%CI=0.3,1.77,P=.485)。患有精神障碍的参与者更有可能被开具抗抑郁药(OR=2.12,95%CI=1.06,4.22,P=.033)、抗精神病药(OR=3.57,95%CI=1.74,7.32,P=.001)、心境稳定剂(OR=6.61,95%CI=1.51,28.97,P=.012)和苯二氮䓬类药物(OR=2.22,95%CI=1.11,4.43,P=.024)。
本研究为关于患有精神障碍且接受MMT治疗的OUD个体的结果的稀少文献做出了贡献。治疗留存率和阿片类物质使用情况令人鼓舞,与普遍认为这些个体治疗效果较差的观点形成对比。该组中镇静和延长QTc药物的联合处方率较高可能带来独特的安全问题。